u/Capital_Letterhead49

$PGEN Follow-Up — Did anyone here actually ride this thesis with me?

Hey Traders,

I posted my original thesis on $PGEN when this was still mostly a story about potential.

Back then the big question was simple:

Can PAPZIMEOS actually become a real commercial biotech success?

Well… now we have the first real answer.

Q1 just dropped, and honestly, this was a much stronger report than what many expected.

Key takeaways:

• PAPZIMEOS delivered $21.6M in net product revenue in its first real commercial quarter

• Approximately 400 patients enrolled in the patient hub

• 25% of enrollment now coming from community settings (important because this shows adoption beyond major academic centers)

• Coverage now reaches ~297M insured lives (>90% of insured US population)

• Permanent reimbursement J-code now active

• Management says current cash + expected PAPZIMEOS revenue should fund operations to cash flow breakeven by end of 2026

That last part matters.

Because one of the biggest bear arguments was always:

“Great science… but inevitable dilution.”

That thesis just got weaker.

The commercial story now looks much more real.

This is what changes biotech valuations:

Not press releases.
Not hype.
Not pipeline dreams.

Commercial execution.

What I find interesting:

The market was treating PGEN like another speculative biotech…

but this may be transitioning into a legitimate commercial growth story.

Now the next question becomes:

Can Q2 confirm acceleration?

Because if PAPZIMEOS continues ramping, valuation assumptions may need to be repriced.

I’ve been following this story closely since before approval, and I’m curious:

Did anyone here actually take the original thesis with me?

Would love to hear how others are positioning after this earnings report.

Not financial advice. Do your own DD.

reddit.com
u/Capital_Letterhead49 — 16 hours ago

Anyone who followed my HPE thesis

Hey traders, anyone who followed my HPE thesis — how’s it going for you so far?

I’d genuinely love to hear if anyone here took the trade.

I’m still holding my common shares, and today I also added HPE $31 calls (Aug 21 expiry) to increase exposure into the next phase of the move.

My current working thesis?
I think $38 is achievable (BOFA also recently raised their target there), but as always… markets don’t move on targets alone. they move on narrative, momentum, and execution.

So we’ll see how the story evolves.

About two months ago, I posted my original HPE thesis.

Original entry: $23.22

HPE today: ~$32

That’s roughly a +37% move on shares, and what’s interesting is that the thesis didn’t just work…

it actually evolved into something stronger.

Original thesis

This wasn’t a random AI momentum chase.

While everyone was piling into NVDA / SMCI / hyperscaler names, I was looking for a laggard inside the broader AI infrastructure ecosystem.

What stood out:

  • Tight multi-week consolidation
  • Higher lows forming
  • Quiet volume accumulation
  • Clean breakout setup
  • Sector rotation into second-wave AI infrastructure

The structure looked textbook:

Accumulation → Breakout → Expansion

The trigger was clear:

once HPE cleared the $23–24 resistance zone, the setup confirmed.

That’s where conviction came from.

Not before.

What changed since then

This is where it gets interesting.

The original thesis didn’t break.

It got stronger.

1) Activist pressure entered the story

Now we have:

  • Elliott Management
  • Irenic Capital

taking positions / applying pressure.

That changes perception dramatically.

This is no longer just:

“boring enterprise hardware.”

Now the market starts asking:

Is there unlocked shareholder value here?

That’s a major catalyst.

2) The Juniper acquisition changed the company profile

The $14B Juniper acquisition was a huge strategic shift.

HPE is no longer viewed purely as legacy enterprise infrastructure.

Now the story includes:

  • networking
  • AI data center infrastructure
  • enterprise compute
  • broader AI ecosystem exposure

That matters for rerating.

3) Analysts started repricing the stock

Bank of America moved their target to $38.

Other analysts have also become more constructive.

Whether price gets there or not isn’t the point.

The point is:

institutional narrative is changing.

Technical update

The old breakout thesis played out almost exactly as expected.

Back then:

base → breakout setup

Now:

full trend expansion.

Current technical structure:

  • higher highs
  • higher lows
  • breakout above long-term resistance
  • clean trend structure
  • strong moving average alignment
  • momentum still intact

Yes, short-term it looks extended.

But structurally?

Still bullish.

Position update

I’m still holding common shares.

Today I added:

HPE $31 Calls (Aug 21 expiry)

Why?

Because I think there’s still room if:

  • earnings hype builds
  • activist pressure continues
  • AI infra narrative expands
  • momentum funds keep rotating in

That said:

I’m managing this as a trade.

Not marrying the position.

Biggest lesson

The biggest money usually isn’t made chasing obvious names after everyone agrees.

It’s made by finding quality setups before the narrative fully matures.

Everyone wanted the next NVDA.

Sometimes the better trade is:

the second-wave AI infrastructure name nobody was watching.

Curious if anyone else here has been in HPE or sees similar setups developing elsewhere.

u/Capital_Letterhead49 — 18 hours ago
▲ 4 r/BullsAndBearsTrading+1 crossposts

$PGEN Earnings Watch — What REALLY matters this quarter, especially 9 months after I made my original post about the company’s first FDA-approved drug.

Hey Traders: Back then, the story was mostly about potential.

Today, things are different:

  • PAPZIMEOS is approved.
  • Commercial launch is active.
  • CMS reimbursement is now in place.
  • Institutions continue increasing positions.
  • Revenue is finally starting to show up.

Now the big question becomes:

Is commercialization actually working?

Here’s what I’ll personally be watching during earnings:

  1. Patient growth / enrollment This is probably the MOST important metric right now. Wall Street wants evidence that adoption is accelerating after approval and reimbursement support.
  2. Revenue growth trajectory Not just current revenue, but management guidance moving forward. The market wants to see whether PAPZIMEOS can scale into a meaningful commercial product.
  3. Commentary around demand Are physicians prescribing? Are patients gaining access faster? Any acceleration in uptake could change valuation expectations quickly.
  4. Cash runway / dilution risk This still matters. Even strong biotech stories can get hurt if cash burn remains too high.
  5. Future expansion opportunities Europe, pediatrics, and the broader pipeline could become major long-term catalysts.

What’s interesting to me is that institutional accumulation continues increasing:

  • Vanguard added heavily.
  • BlackRock and State Street remain involved.
  • Multiple funds increased positions recently.

That doesn’t guarantee success, but it does suggest Wall Street is taking this commercial launch seriously.

Analyst targets are currently sitting around:
$9–$10 average targets

And remember:
those targets are usually based on moderate commercialization assumptions. not blue-sky scenarios.

Personally, I think this earnings call matters less for EPS and more for proving:
“Can PAPZIMEOS become a real commercial biotech success story?”

That’s the key.

I currently hold shares and plan to continue following the story closely.

Curious to hear what everyone else is expecting from this earnings report.

Not financial advice. Do your own DD.

reddit.com
u/Capital_Letterhead49 — 2 days ago
▲ 2 r/BullsAndBearsTrading+1 crossposts

$SOFI for roughly the last 12 months

I’ve been following SoFi ($SOFI) for roughly the last 12 months, watching how the market narrative around the company has constantly shifted.

After reviewing this latest earnings report, I still see several important things worth monitoring.

• Revenue grew 43% YoY, surpassing $1.1B.

• EPS came in positive again, and management maintained strong 2026 guidance.

• Deposits are now above $40B, which is important because it lowers funding costs and strengthens the banking model.

• Loan originations continue growing aggressively.

But honestly, I think the real debate around SOFI is still not fully resolved.

For more than a year, a meaningful part of the market has maintained short positions against the stock, mainly because many believe:

• The rapid growth in personal loans could eventually hurt credit quality.

• If the economy weakens, defaults could rise.

• The business model still hasn’t been fully tested through a difficult economic cycle.

And in fact, while credit metrics still appear relatively controlled, charge-offs did increase sequentially from the prior quarter. That helps explain why many shorts still haven’t disappeared.

On the other hand, there are also things the market can no longer ignore:

• SOFI no longer looks like just a speculative fintech.

• It now has massive deposits, positive profitability, and a structure that increasingly resembles a real digital bank.

• It also continues expanding members, products, and its financial ecosystem.

What’s interesting is that the stock has traded mostly sideways for quite a while, roughly between $10 and $32 over the last year, and more recently closer to the $16–20 range.

Even after this latest report, it still doesn’t look like institutions are aggressively chasing the stock higher. The market seems to still want more evidence that this growth is truly sustainable.

Personally, I’m not posting this as financial advice or as a bullish or bearish call.

I’m simply continuing to observe how the story evolves, because I think SOFI’s future ultimately comes down to one key question:

Is the company building a scalable and profitable digital bank… or simply expanding credit risk too aggressively?

That question will probably determine where this stock trades over the next several years.

Curious to hear how others are viewing SOFI at this stage.

u/Capital_Letterhead49 — 6 days ago

r/SRPT – Still Watching After 8 Months

Traders:

https://investorrelations.sarepta.com/node/25206/pdf

About 8 months ago, I exited my position in Sarepta Therapeutics (SRPT). At the time, the story was becoming too dependent on uncertainty around ELEVIDYS, regulatory pressure, and whether the company could actually transition into a sustainable commercial biotech business.

Since then, I’ve continued following the stock closely.

What’s interesting now is that the latest earnings may have changed the conversation a bit.

A few things stand out to me:

• SRPT is no longer just a “hope and pipeline” biotech.

The company generated meaningful revenue and positive EPS this quarter.

• The market narrative is evolving beyond only ELEVIDYS.

Now there’s increasing focus on the siRNA platform, FSHD, DM1, and broader long-term pipeline potential.

• The refinancing and runway situation also improved significantly.

The 2030 convertible notes removed near-term funding pressure, which matters a lot for biotech names.

At the same time, the risks are still very real:

• ELEVIDYS remains controversial.

• Black box liver warnings and safety concerns are serious.

• FDA restrictions for non-ambulatory patients are still a major overhang.

• This is still a high-volatility biotech stock.

What I find interesting is that despite all the negative headlines over the last several months, SRPT has continued operating, generating revenue, and expanding pipeline visibility.

So for now, I’m not posting this as a bullish call or financial advice.

I’m simply keeping SRPT on my watchlist and continuing to observe whether the company is truly transitioning from a speculative biotech story into a more established commercial biotech platform.

That distinction will probably determine where this stock trades over the next few years.

Curious to hear how others are viewing SRPT at this stage.

reddit.com
u/Capital_Letterhead49 — 8 days ago